CHIMERIX INC
chimerix.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2024 10-K, filed Mar 21, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 13, 2025.
10-K for FY2024, filed Mar 21, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops imipridone cancer drug candidates, including dordaviprone, for patients with glioma and other central nervous system tumors.
10-K for FY2024, filed Mar 21, 2025Chimerix (Chimerix, we, our, us or the Company) is a biopharmaceutical company whose mission it is to develop medicines that meaningfully…View ↗
How Did They Make Money?
Federal agencies and private foundations provide grants and contracts; Chimerix counts revenue as it fulfills the work promised under each agreement. Other sources include TEMBEXA sales and license upfront fees, milestones and royalties.
-
10-K for FY2024, filed Mar 21, 2025
FY2024 revenue by product or service ↗
$212K
-
10-K for FY2024, filed Mar 21, 2025
$212K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Procurement revenue
|
0.0%
FY2021: 0.0%
|
Procurement revenue, FY2024
$0 Sources
|
|
|
Contract and grant revenue
|
100%
FY2021: 97%
|
Contract and grant revenue, FY2024
$212K Sources
|
|
|
Licensing revenue
Licensed
|
0.0%
FY2021: 2.6%
|
Licensing revenue, FY2024
$0 Sources
|
Licensed |
|
Royalty revenue
Licensed
|
0.0%
FY2021: 0.0%
|
Royalty revenue, FY2024
$0 Sources
|
Licensed |
Who Were Their Customers?
Federal agencies and private foundations provide funding through grants and contracts.
10-K for FY2024, filed Mar 21, 2025The Company’s revenues generally consist of (i) contract and grant revenue—revenue generated under federal government and private…View ↗
Did Revenues Turn Into Profits?
No. It lost $88.4M in FY2024.
10-K for FY2024, filed Mar 21, 2025
−$96.6MView ↗
10-K for FY2024, filed Mar 21, 2025
−$88.4MView ↗
10-K for FY2024, filed Mar 21, 2025
−$75.3MView ↗
How Were They Changing?
-
Apr 21, 2025
The merger made Chimerix a wholly owned subsidiary
Chimerix requested suspension of trading and delisting from Nasdaq.
Sources
8-K, filed Apr 21, 2025
As described in the Introductory Note above, on April 21, 2025, Purchaser irrevocably accepted for payment all Shares validly tendered and…View ↗
Shrank. Revenue fell 96% in 4 years, from $5.4M in FY2020 to $212K in FY2024, about 55% a year.
Loading...
